medac Pharma announce end of agreement to promote and distribute CHEMOSAT® in the UK

medac Pharma announce that they will no longer be responsible for CHEMOSAT®, used in percutaneous hepatic perfusion for liver metastases. As of the 1^st of March 2022 responsibility for this product will be handed over to Delcath Systems Limited, Galway, Ireland.

For further information on CHEMOSAT® please use the contact details below;

Evelyn Glynn
​EMEA Marketing Director
​Tel: +353 91 746210 (office); +353 87 6369747 (mobile)
​Email: [email protected]

For CHEMOSAT orders please contact:
​​
​Sarah Donnelly
​EMEA Financial Controller
​Tel.: +353 91 746220; Fax: + 353 91 746208
​Email : [email protected]